Efficacy of the Cosmetic Product "Onco-Repair" on Grade 2 Hand Foot Syndrome
NCT03612011 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 72
Last updated 2019-09-06
Summary
The aim of the study is to assess the restorative efficacy of the cosmetic product "Onco-Repair" vs placebo of the most affected palmer face in subject with grade 2 HFS induced by targeted therapies or conventional chemotherapy.
Conditions
- Grade 2 Hand-foot Syndrom
Interventions
- OTHER
-
Onco-Repair/ Placebo
Cream must be applied twice a day, in the morning and evening, on the hands and feet (palmo-plantar areas and interdigital spaces included) previously cleaned with Atoderm Intensive Foaming Gel, chosen as a standardized hygiene product.
Sponsors & Collaborators
-
NAOS Institute of Life Science
collaborator INDUSTRY -
Quanta Medical
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-07-12
- Primary Completion
- 2018-08-01
- Completion
- 2019-06-02
Countries
- France
Study Locations
More Related Trials
-
Study of NC-6004 in Combination With 5-FU and Cetuximab in Patients With Head and Neck Cancer
NCT02817113 ·Status: TERMINATED ·Phase: PHASE1
-
Combination Chemotherapy and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer
NCT00352118 ·Status: TERMINATED ·Phase: PHASE2
-
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
NCT02128906 ·Status: RECRUITING ·Phase: PHASE2
-
Trial Evaluating Adapted Chemotherapy in Patients With Squamous Carcinoma
NCT04356170 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC
NCT06855212 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Operable Patients
NCT02099175 ·Status: UNKNOWN ·Phase: PHASE2
-
Copanlisib in Association With Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas Harboring a PI3KCA Mutation/Amplification and/or a PTEN Loss
NCT02822482 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT01154920 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Predicting Immunotherapy Efficacy in Head and Neck Squamous Cell Cancer
NCT05296135 ·Status: WITHDRAWN
-
Docetaxel and S-1 Followed By Radiation Therapy and Low-Dose Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer
NCT00625937 ·Status: UNKNOWN ·Phase: PHASE2
-
SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma
NCT07254585 ·Status: RECRUITING ·Phase: PHASE2
-
Metformin Hydrochloride in Combination With Standard of Care Systemic Therapy in Previously Untreated Advanced Unresectable or Metastatic Soft Tissue Sarcoma
NCT07291297 ·Status: RECRUITING ·Phase: PHASE2
-
Pilot Study of Management of Facial Paralysis in the Oncologic Patient: Nerve Transfer Techniques to Improve Facial Function and Quality of Life
NCT06667427 ·Status: RECRUITING ·Phase: NA
-
Interstitial Photodynamic Therapy in Treating Patients With Recurrent Head and Neck Cancer
NCT02068157 ·Status: TERMINATED ·Phase: PHASE2
-
AK104 and Low-dose Radiation in Recurrent/Metastatic HNSCC After Failure of First-line Systemic Therapy
NCT06494995 ·Status: RECRUITING ·Phase: PHASE2
-
Study of Induction Docetaxel, Cisplatin and 5-Fluorouracil
NCT00400205 ·Status: TERMINATED ·Phase: PHASE2
-
Combination Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
NCT00139230 ·Status: COMPLETED ·Phase: PHASE2
-
Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Head and Neck Squamous Cell Carcinomas
NCT06109207 ·Status: RECRUITING ·Phase: PHASE1
-
SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCC
NCT06989671 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Study of Cetuximab in Squamous Cell Carcinoma of the Skin Expressing EGFR
NCT00240682 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Study of RAD001 Head and Neck Cancer
NCT01051791 ·Status: TERMINATED ·Phase: PHASE2
-
Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery
NCT01468896 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Cancer
NCT00768664 ·Status: COMPLETED ·Phase: PHASE2
-
Camrelizumab in Combination With Cetuximab and Chemotherapy for Relapsed/Metastatic HNSCC Patients
NCT05673577 ·Status: COMPLETED ·Phase: PHASE2
-
DAHANCA 30: A Randomized Non-inferiority Trial of Hypoxia-profile Guided Hypoxic Modification of Radiotherapy of HNSCC.
NCT02661152 ·Status: UNKNOWN ·Phase: PHASE3